Gas-filled phospholipid-based ultrasonic microbubbles (PUMs) are widely used in diagnostic imaging. The micro- or nanoparticle size and the physiochemical nature of shell provide the potential for a new way to improve pulmonary absorption for peptides and proteins.
Methods:
Male Sprague–Dawley rats were fasted for 12 h. Then insulin solution and insulin–PUM mixture solution were administered by intratracheal instillation. The hypoglycemic effect was observed to evaluate insulin absorption after lung administration. Fluorescein isothiocyanate–dextran (molecular mass, 4 kDa) was used as the index of evaluating drug alveolar deposition and absorption by visualization techniques.
Results:
Administration of insulin solution containing PUMs significantly reduced the blood glucose levels of Sprague–Dawley rats, compared with administration of insulin-only solution. The minimum reductions of the blood glucose concentration produced by insulin solution containing PUMs and by an insulin-only solution reached 60.81% and 34.60% of the initial glucose levels, respectively, and their bioavailabilities relative to subcutaneous injection were 48.58% and 29.09%, respectively. Histopathological study of the lung showed no changes in the morphology of the pulmonary alveoli after administration to these drugs. Only a slight inflammatory cell infiltration in the alveoli could be found in some rats.
Conclusion:
These results suggested that PUMs might be used as an effective way to improve pulmonary absorption for peptides and proteins.
Get full access to this article
View all access options for this article.
References
1.
PattonJS, ByronPR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov, 2007; 6:67–74.
2.
WinklerJ, HochhausG, DerendorfH. How the lung handles drug: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc, 2004; 1:356–363.
3.
MasahiroS. In vivo, In vitro, and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev, 2006; 58:1030–1060.
4.
MalgorzataS, ThierryV, AdamS. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory disease. Int J Nanomed, 2008; 3:1–19.
5.
KwonJH, LeeBH, LeeJJ, KimCW. Insulin microcrystal suspension as a long-acting formulation for pulmonary delivery. Eur J Pharm Sci, 2004; 22:107–116.
6.
SakagamiM. Insulin disposition in the lung following oral inhalation in humans: a meta-analysis of its pharmacokinetics. Clin Pharmacokinet, 2004; 43:539–552.
7.
LimSH, ParkHW, ShinCH, KnowJH, KimCW. Human insulin microcrystals with lactose carriers for pulmonary delivery. Biosci Biotechnol Biochem, 2009; 73:2576–2582.
8.
MorimotoK, MetsugiK, KatsumataH, IwanagaK, KakemiM. Effects of low-viscosity sodium hyaluronate preparation on the pulmonary absorption of rh-insulin in rats. Drug Dev Ind Pharm, 2001; 27:365–371.
9.
ZhaoYZ, LuCT. Recent advances in the applications of ultrasonic microbubbles as gene delivery systems [in Chinese]Yao Xue Xue Bao, 2007; 42:127–131.
10.
ZhouBJ, ZhaDG, DuRS, HuF, WuJF, LiuYL. Impact of ultrasound-mediated microbubbles on myocardial vascular permeability in rats [in Chinese]Nan Fang Yi Ke Da Xue Xue Bao, 2010; 30:239–241.
11.
SunQF, DuF, XuY, YangPS. Ultrasound-mediated microbubble destruction enhances bone morphogenetic protein-2 gene expression in mouse skeletal muscles [in Chinese]Hua Xi Kou Qiang Yi Xue Za Zhi, 2009; 27:84–87.
12.
RapoportNY, EfrosAL, ChristensenDA, KennedyAM, NamKH. Microbubble generation in phase-shift nanoemulsions used as anticancer drug carriers. Bubble Sci Eng Technol, 2009; 1:31–39.
13.
American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care, 2009; 32,Suppl 1:S13–S60.
14.
LucyDM. Inhaled insulin: overview of a novel route of insulin administration. Vasc Health Risk Manage, 2010; 6:47–58.
15.
ChenB, FriedmanB, ChengQ, TsaiP, SchimE, KleinfeldD, LydenPD. Severe blood-brain barrier disruption and surrounding tissue injury. Stroke, 2009; 40:e666–e674.
16.
Skalko-BasnetN, TohdaM, WatanabeH. Uptake of liposomally entrapped fluorescent antisense oligonucleotides in NG108-15 cells: conventional versus pH-sensitive. Biol Pharm Bull, 2002; 25:1583–1587.
17.
TrachselS, KellerHU. Selective responses (actin polymerization, shape changes, locomotion, pinocytosis) to the PKC inhibitor Ro 31-8220 suggest that PKC discriminately regulates functions of human blood lymphocytes. J Leukoc Biol, 1995; 57:587–591.
18.
ZhaoYZ, LuoYK, LuCT, MeiXG, TangJ, ZhangY, LiangHD. Phospholipids-based microbubbles pore sonoporation size and reseal of cell membrane cultured in vitro. J Drug Target, 2008; 16:18–25.
19.
ZhaoYZ, LuoYK, LiangHD, MeiXG, TangJ, LuCT, ZhangY, LinQ. Comparing transfection efficiency and safety for antisense oligodeoxyribonucleotide between phospholipids-based microbubbles and liposomes. J Drug Target, 2006; 14:687–693.
20.
SchankerLS, BurtonJA. Absorption of heparin and cyanocobalamin from the rat lung. Proc Soc Exp Biol Med, 1976; 152:377–380.
21.
ChenXJ, ZhuJB, WangGJ, ZhouMX, XinFM, ZhangN, WangCX, XuYN. Hypoglycemic efficacy of pulmonary delivered insulin dry powder aerosol in rats. Acta Pharmacol Sin, 2002; 23:467–470.
22.
LengG, KongXZ. Preparation and pharmacodynamic study of insulin microsphere for intranasal administration. China Pharmacy, 2003; 14:277–278.
23.
ElliottRB, EdgarBW, PilcherCC, QuestedC, McMasterJ. Parenteral absorption of insulin from the lung in diabetic children. Aust Paediatr J, 1987; 23:293–297.
24.
MandalTK. Inhaled insulin for diabetes mellitus: factors affecting the pulmonary delivery of insulin. Am J Health System Pharmacy, 2005; 62:1359–1364.
25.
BiR, ShaoW, WangQ, ZhangN. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J Drug Targeting, 2008; 16:639–648.
26.
OkumuraO, IwakawaS, YoshidaT, SekiT, KomadaF. Intratracheal delivery of insulin absorption from solution and aerosol by rat lung. Int J Pharm, 1992; 88:63–73.
27.
ShinzoK, ShujiK, KazuhikoJ. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm Res, 1996; 13:80–84.
28.
MasamiS, MinoruM, KenjiA, KoujiO, TetsuroS, MasahiroH, ShojiA. Histopathological study of the effects of a single intratracheal instillation of surface active agents on lung in rats. J Toxicol Sci, 2000; 25:49–55.
29.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med, 1993; 329:977–986.
30.
JuffermansLJ, KampO, DijkmansPA, VisserCA, MustersRJ. Low-intensity ultrasound-exposed microbubble provoke local hyperpolarization of the cell membrane via activation of BKCa channels. Ultrasound Med Biol, 2008; 34:502–508.
31.
ShashankS. Microbubble compositions, properties and biomedical applications. Bubble Sci Eng Technol, 2009; 1:3–17.
32.
VerderH, EbbesenF, LinderholmB, RobertsonB, EschenC, Arrø eM, LangeA, GrytterC, BohlinK, BertelsenA. Prediction of respiratory distress syndrome by the microbubble stability test on gastric aspirates in newborns of less than 32 weeks' gestation. Acta Paediatr, 2003; 92:728–733.
33.
JinLT, LiXK, CongWT, HwangSY, ChoiJK. Pre-visible silver staining of protein in electrophoresis gels with mass spectrometry compatibility. Anal Biochem, 2008; 383:137–143.
